Nothing Special   »   [go: up one dir, main page]

Bastus et al., 2008 - Google Patents

Reactivity of engineered inorganic nanoparticles and carbon nanostructures in biological media

Bastus et al., 2008

Document ID
12944531740468335011
Author
Bastus N
Casals E
Vázquez-Campos S
Puntes V
Publication year
Publication venue
Nanotoxicology

External Links

Snippet

Biocompatibility, biodistribution, biodegradation, inflammation and interference with cell and normal functioning of tissues, among others, will determine the toxicity of engineered inorganic nanoparticles and carbon nanostructures, and therefore the extent of their use …
Continue reading at www.tandfonline.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
    • A61K47/48861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being an inorganic particle, e.g. a ceramic particle, silica particle, ferrite, synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
    • A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
    • A61K47/48876—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being a solid micro- or nanoparticle having no hollow or gas-filled core
    • A61K47/48884—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being a solid micro- or nanoparticle having no hollow or gas-filled core the form being a nanoparticle, e.g. an immuno-nanoparticle
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANO-TECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANO-STRUCTURES; MEASUREMENT OR ANALYSIS OF NANO-STRUCTURES; MANUFACTURE OR TREATMENT OF NANO-STRUCTURES
    • B82Y30/00—Nano-technology for materials or surface science, e.g. nano-composites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANO-TECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANO-STRUCTURES; MEASUREMENT OR ANALYSIS OF NANO-STRUCTURES; MANUFACTURE OR TREATMENT OF NANO-STRUCTURES
    • B82Y5/00—Nano-biotechnology or nano-medicine, e.g. protein engineering or drug delivery

Similar Documents

Publication Publication Date Title
Bastus et al. Reactivity of engineered inorganic nanoparticles and carbon nanostructures in biological media
Husen et al. Advances in smart nanomaterials and their applications
Abbasi et al. Structural parameters of nanoparticles affecting their toxicity for biomedical applications: a review
Nyoka et al. Synthesis of cerium oxide nanoparticles using various methods: implications for biomedical applications
De Matteis et al. Toxicity assessment in the nanoparticle era
Casals et al. Reactivity of inorganic nanoparticles in biological environments: insights into nanotoxicity mechanisms
Oberdörster et al. Toxicology of nanoparticles: a historical perspective
Kong et al. Experimental considerations on the cytotoxicity of nanoparticles
Viswanath et al. Influence of nanotoxicity on human health and environment: The alternative strategies
Papp et al. Human health implications of nanomaterial exposure
Curtis et al. Nanotechnology and nanotoxicology: a primer for clinicians
Lee et al. High temperature decomposition of cerium precursors to form ceria nanocrystal libraries for biological applications
Karlsson et al. Toxicity of metal and metal oxide nanoparticles
Karlsson et al. Toxicity of metal and metal oxide nanoparticles
Mukherjee et al. Toxicological concerns of engineered nanosize drug delivery systems
Rathore et al. Toxicology and Toxicity Studies of Nano-Biomaterials
Hoet et al. Do nanomedicines require novel safety assessments to ensure their safety for long-term human use?
Haase et al. Nanomaterials: a challenge for toxicological risk assessment?
Gaihre et al. Encapsulation of Fe3O4 in gelatin nanoparticles: Effect of different parameters on size and stability of the colloidal dispersion
Odaudu et al. Toxicity and cytotoxicity effects of selected nanoparticles: a review
Syama et al. The promising biomedical applications of engineered nanomaterials
Prajapati et al. Nano particles: Pioneering the future of drug delivery and beyond
Rashdan et al. Nanoparticles for biomedical applications: current status, trends and future challenges
Kerin et al. Review on aquatic toxicity of metal oxide nanoparticles
Sher et al. Magnetic multifunctional nanomaterials for enhanced transverse chemical and bioanalytical applications–A review